Familial Multiple Myeloma: Report on Two Families and Discussion of Screening Options by Gerkes, Erica H et al.
H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2007; 5(2) 72
Hereditary Cancer in Clinical Practice 2007; 5(2) pp. 72-78
Familial Multiple Myeloma: Report on Two Families and Discussion 
of Screening Options
Erica H. Gerkes
1, Mirjam M. de Jong
1, Rolf H. Sijmons
1, Edo Vellenga
2
1 Department of Genetics, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands
2 Department of Haematology, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands
Key words: multiple myeloma, familial, screening
Corresponding author: Erica H. Gerkes, M.D., Department of Genetics, University Medical Centre Groningen, Hanzeplein 1,
PO Box 30.001, 9700 RB Groningen, the Netherlands, tel.: +31 50 3617235, e-mail: E.H.Gerkes@medgen.umcg.nl
Submitted: 15 May 2007
Accepted: 4 June 2007
A Ab bs st tr ra ac ct t
Multiple myeloma (MM) is a relatively rare haematological malignancy seen in older persons. It has an unknown
aetiology and usually occurs incidentally within a family. However, several families have been reported with
multiple cases of MM, so that the existence of hereditary MM has been postulated although no causative germline
mutations have been detected so far. First-degree relatives of MM patients have been reported to have a relative
risk between two and four times higher than normal of developing MM and we presume the risks are higher for
relatives in the case of familial MM. Here we report on two families with MM who requested presymptomatic
screening of healthy relatives. Although risk estimates for asymptomatic relatives in these types of families are
not available, a clinically significant risk of developing MM cannot be excluded. We suggest that, in a research
setting, screening for MM could be offered to individuals with more than one first-degree affected relative, or
to those with one first-degree and at least one second-degree relative with MM. We propose a screening
programme of annual protein electrophoresis of blood and urine, starting at age 40 (or earlier if a family
member presented with MM at a younger age).
I In nt tr ro od du uc ct ti io on n
Multiple myeloma (MM) is a haematological
malignancy characterised by a malignant proliferation of
monoclonal plasma cells in the bone marrow producing
monoclonal immunoglobulins and by the formation of
focal osteolytic lesions in the skeleton. The disorder might
evolve from a common pre-malignant condition called
monoclonal gammopathy of undetermined significance
(MGUS). However, the factors driving the malignant
transformation of MGUS are as yet unknown. The clinical
manifestations of MM include bone pains caused by lytic
bone lesions, anaemia, hypercalcaemia, immunodefi-
ciency and renal failure [1, 2]. The incidence of the disease
is about 3 to 4 per 100,000 in the Netherlands and
mortality rates are only slightly lower [3]. Although the
disorder is not curable in most cases, the overall survival
varies depending on the age of onset and other prognostic
features. The five-year survival rate is approximately 30%
[1, 3, 4].
MM usually occurs incidentally within a family.
However, several families have been described with
multiple cases of MM, suggesting there may be
a genetic predisposition [5-11]. Since no causative
germline gene mutations have been identified,
diagnostic DNA testing of families with an inherited
type of MM and presymptomatic genetic screening for
unaffected relatives are unavailable.H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2007; 5(2) 73
Here we report on two families with familial
clustering of MM, we review the literature on
familial MM, and we discuss the options for screening
healthy relatives for MM in these familial cases.
C Ca as se e   r re ep po or rt ts s
Two unrelated families were referred to our clinic
asking about the possible heritability of MM in their
family and the options for screening of healthy relatives.
The patients’ medical records were reviewed.
Family 1 had three first-degree relatives affected
by MM (Figure 1). The index patient (III-2) was 
a 65-year old female who was diagnosed with MM after
presenting with pain in the shoulder region and fatigue.
She had an IgG paraproteinaemia of 32 g/l, which
later rose to 53 g/l, and 65 percent bone marrow
plasma cells. Cytogenetic findings in bone marrow
corresponded with this diagnosis (46,XX [6], 54
–X, 1q+, +1p–, +3, +5, +6q–, +9, 11q+,
–13, 14q+, +15, +16, +19, +20 [4]). She was
treated with intensive chemotherapy and autologous
stem cell transplantation. Her father (II-3) had been
diagnosed with MM at 71 years of age after the
discovery of a lytic lesion in the spine and an IgG
paraproteinaemia. No cytogenetic analysis was
performed. He was treated with chemotherapy and
radiotherapy. Four years after the diagnosis he died
from complications due to MM. The brother of the
index patient (III-1) had been diagnosed with MM at
45 years of age. He had several lytic bone lesions in
his spine and pelvis and an IgG paraproteinaemia
F Fi ig g. . 1 1. .   Pedigree of family 1 with multiple myeloma. Diagnosis and age of diagnosis are given, as well as age of death. Solid blocks represent
patients with multiple myeloma; open blocks represent patients without multiple myeloma. Diagonal lines indicate deceased individuals, 
and the arrow indicates the proband. The roman numbers in the left margin refer to the different generations. MM = multiple myeloma; 
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of 140 g/l. Cytogenetic analysis of bone marrow
showed no abnormalities (46,XY [10]). He was treated
with intensive chemotherapy, radiotherapy and
autologous stem cell transplantation. Six years after
diagnosis he died of complications due to MM.
The mother of the index patient died of leukaemia
(type unknown) at 75 years of age. No other
haematological malignancies were reported in the
family. Two of the patient’s paternal uncles died of lung
cancer at an old age (smoking habits unknown). There
was no known shared or individual exposure to toxic
chemicals or radiation in the patients.
Family 2 had two first-degree relatives affected
by MM (Figure 2). The index patient is a 38-year old male
who was diagnosed with MM after discovery of a lytic
lesion in the hip. He had an IgG paraproteinaemia of 37
g/l and six percent bone marrow plasma cells.
Cytogenetic findings in bone marrow were normal (46,XY
[10]). He underwent radiotherapy, intensive chemotherapy
and stem cell transplantation.
His father was diagnosed with MM at the age
of 60 years after having a pathological fracture of the
upper arm. He had an IgA-lambda paraproteinaemia
of 14 g/l and thirty percent bone marrow plasma cells.
Cytogenetic findings in bone marrow corresponded
with this diagnosis (46,XY [4], 58,XY, +3, +5, +6, 
t(8; 22)(q24; q11), +9, +11, +15, +18, +19, +21
[6]). He was treated with intensive chemotherapy and
autologous stem cell transplantation.
The patterns of other types of cancer seen in these
two families did not suggest any known hereditary
cancer syndrome.
D Di is sc cu us ss si io on n
Multiple myeloma is a relatively rare haematological
malignancy of older persons. It has an unknown
aetiology. It usually occurs incidentally within a family, but
several familial cases have been reported in the literature
[5-11]. The frequency of familial MM seems to be
approximately 3.2 per 1000 cases of MM, leading to an
occurrence of familial MM in approximately 1 per 10
million persons per year, making it a rare event [5].
The familial clustering of MM might be explained
in several ways. Shared environmental factors have
been implicated, for example radiation and pesticide
exposure were reported to have led to a higher
incidence of MM [12-13]. However, Alexander et al.
concluded that no environmental risk factors could
consistently be established when they compared
multiple epidemiologic studies on environmental
influences [14]. Chance alone might have caused the
clustering within families; however, several families have
shown an inheritance pattern that is very suggestive of
an underlying genetic factor. A number of authors have
proposed an autosomal dominant mode of inheritance,
with reduced penetrance, to explain the occurrence of
multiple cases of MM within a family [6-11, 15].
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Engelhardt et al. postulated an autosomal
recessive inheritance with low penetrance based on
their findings of a high prevalence of B-cell diseases
(MM or MGUS – monoclonal gammopathy of
unknown origin) among siblings of MM patients.
However, they only screened siblings and showed no
data on paternal or offspring disease state [16].
Both our families would fit the hypothesis of an
autosomal dominant pattern of inheritance, although
environmental agents, low penetrance predisposing
genes, or clustering by chance – or combinations of
these – could be alternative explanations for the
familial pattern. Unfortunately, because of the small
number of informative meioses and the lack of DNA
samples from some of the affected relatives, linkage
analysis cannot be expected to solve the puzzle in these
two families.
In the first family all three affected persons had an
IgG paraproteinaemia, which might suggest
a common genetic cause, but in the second family the
type of monoclonal immunoglobulin differed between
the two patients. A discrepancy in type of
immunoglobulin produced within a family was also
shown by Lynch et al. [6] in an MM/MGUS family and
also by Ogmundsdottir [17].
Some studies suggest that germline gene mutations
and polymorphisms may be associated with a risk
of MM; however, results have not been consistent and
no causative inherited genetic factor has been detected
so far [14, 18].
It has been well established that MM is
characterised by extensive genomic abnormalities in
tumour cells. The abnormalities consist of numerical
and gross structural changes, deletions, duplications
and translocations. These changes are also found in
most patients with MGUS. Some of these somatic
cytogenetic defects have major prognostic value [19-20].
Only two of the patients in our families showed
characteristic complex chromosomal changes, refuting
a relation between specific somatic chromosomal
abnormalities and constitutional genetic factors.
However, only conventional cytogenetic analysis was
performed in our patients. In theory, small structural
chromosomal changes (shared by relatives) could have
been overlooked due to the limited spatial resolution
of the technique.
F Fa am mi il ly y  h hi is st to or ry y  a an nd d  c ca an nc ce er r  r ri is sk k
Because no genetic factor or exact mode of
inheritance has been determined for MM, the risk for
healthy relatives of MM patients can only be estimated
from large case-control or cohort studies. Altiery et al.
quantified the familial risk of MM by studying 11,752
patients with MM. They observed 32 familial cases.
These cases showed an SIR (standardised incidence
ratio) of MM in offspring from an affected parent
of 2.45. The SIR of MM in siblings of an affected
person was 2.44. The risk was highest for daughters
of an affected mother (SIR 5.49) [10]. Landgren et al.
conducted a case-control study to evaluate the risk of
developing MM for someone with first-degree relatives
with MM. They found a significantly increased risk
for MM in relatives of cases (RR (relative risk) 1.67).
Among female relatives, risks were almost four times
higher [11]. No explanation was found for this gender
difference. Hemminki found an SIR of 4.25 for MM
among offspring with a parent presenting with MM
[21]. Eriksson et al. calculated an RR of 5.64 for
first-degree relatives of MM patients [22]. The Swedish
national cancer registers were used for the above
studies. Outcomes presumably vary because they used
different cohorts and different statistical methods.
Brown et al. found an almost four-fold excess risk
for MM in a large case-control study in the US among
subjects with a first-degree relative with MM [23].
From the Icelandic Cancer Registry, Ogmundsdottir
et al. calculated a significantly increased risk of
developing MM for first-degree relatives (RR 2.33), with
the risk being largest for female relatives (RR 3.23)
[17]. Overall, the risk of MM in first-degree relatives
of cases with MM seems to be between two- and
four-fold. Similar familial risks have been reported for
cancers with a known, highly penetrant, predisposition
gene, like breast cancer, colon cancer and ovarian
cancer [9, 24].
To the best of our knowledge, there are no reports
estimating the risk for subjects with more than one (first-
or second-degree) relative suffering from MM, as seen
in our families, but we presume the risks are higher for
relatives of familial cases of MM than for those with
only a single family member suffering from MM.
The risk of developing other types of cancer seems
to be slightly higher for relatives of MM patients. An
increased risk for other lymphoproliferative disorders
in the relatives of MM patients has been shown,
especially for CLL (chronic lymphatic leukaemia) and
NHL (non-Hodgkin lymphoma) [9-11, 23]. Significant
associations were found between MM in a patient and
rectal, stomach, cervical, prostate, bladder, endocrine
gland and connective tissue malignancies in family
members [10, 21-22].
It has been shown that familial cases of MM occur
at an earlier age than sporadic cases, which is
a hallmark of heritable cancer [9-10]. Anticipation, or
the tendency in a multi-generational family for cancer
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to occur earlier in subsequent generations, was
observed in some studies for MM [5, 7-10], but not in
all [25]. In general, anticipation could be explained
by ascertainment bias (due to screening of relatives or
to them being more aware of the disease, thus leading
to earlier discovery) or changes of incidence over time,
but it might also point towards a genetic cause of the
disease [9, 17]. In both our families there seems to be
anticipation. The cancer occurred on average 16 years
earlier in the first family, and 23 years earlier in the
second family.
S Sc cr re ee en ni in ng g  o of f  a as sy ym mp pt to om ma at ti ic c  r re el la at ti iv ve es s  i in n  m mu ul lt ti ip pl le e  
m my ye el lo om ma a  f fa am mi il li ie es s
Patients from families like the ones reported here
often have questions regarding the possibly hereditary
nature of MM in their family and ask if there is a need
to screen healthy relatives. There are no primary
preventive measures for MM as yet [14] and no
consensus guidelines for screening healthy relatives
in MM families. The only recommendation we could find
in the literature is from Hodgson et al., who suggested
screening using blood and urine protein electrophoresis
in first-degree relatives of familial MM patients and
follow-up surveillance of individuals with MGUS, but
they did not specify the frequency of screening or the
preferred age for starting screening [26].
A population with a high risk of MM in which
screening is recommended is the group of patients with
MGUS (monoclonal gammopathy of unknown origin).
MGUS can be seen as a pre-malignant precursor
of MM and it is defined by the presence of a monoclonal
protein, but the absence of a large amount of plasma
cells in the bone marrow and end-organ damage
characteristic for MM (renal insufficiency, lytic bone
lesions, anaemia, hypercalcaemia) [9-14]. MGUS
progresses into MM in about 1% of cases per year and
progression cannot be prevented [27-28]. Periodic
screening is therefore advised for patients with MGUS
in order to detect progression into MM and to prevent
or delay serious complications such as renal failure or
pathologic fractures. The quality of life of patients can
be improved by averting these events and the cost of
long-term dialysis or surgical intervention for skeletal
complications would be reduced [27]. Since there are
no known predictors to indicate which MGUS patients
will progress to MM, screening is recommended for all
patients. The periodic screening should include annual
serum protein electrophoresis [29].
Detection of MGUS in the relatives of MM patients
has been reported several times [5-6, 9, 11]. These
cases were either found by collecting familial cases or
by direct screening of relatives. Lynch et al. reported
on a family with three siblings suffering from MM. After
screening 19 relatives using electrophoresis of urine
and blood, they detected two siblings with MGUS.
These individuals were advised about long-term
follow-up because of their increased risk for MM [9].
When considering the usefulness of a screening
program the Wilson and Jungner criteria are often used
[30]. These indicate that there should be an important
health problem in order to start screening and that it
should only be offered if there is a certain degree of
increased risk. The previously calculated relative risks
(RRs) do not translate into a high lifetime risk because
of the low risk for MM in the general population, and
they therefore do not carry the same weight as similar
RRs that have been calculated for relatives of patients
with common types of cancer like colorectal cancer or
breast cancer [24]. However, although familial MM is
very rare, screening should be offered to selected
families for whom the health problem is significant.
The exact risk is unknown for relatives of familial MM
cases. Calculations did not take more than one
affected relative into account and may therefore have
significantly underestimated the risk for relatives in the
rare families with multiple cases of MM. Indeed, several
observations have suggested the existence of
hereditary MM, and germline gene mutations with
significant penetrance may therefore underlie
familial MM. In the absence of known risk estimates
for the relatives in these families, we conclude for
practical purposes that a significant risk cannot be
ruled out at the present time and the notion of
screening in these families cannot simply be dismissed.
According to the Wilson and Jungner criteria, there
should be a suitable and acceptable diagnostic test for
the disease and good treatment options. Screening
for MM can be done by blood and urine protein
electrophoresis, which is minimally invasive and relatively
easy to perform. On detecting a monoclonal protein,
a distinction between MGUS or MM should be made
by further study, possibly including a bone marrow
biopsy. Treatment options for MM have improved over
the last few years with respect to survival and quality of
life [4, 31].
The goal of cancer screening in general is to detect
a pre-malignant, treatable lesion (as in the case of
screening for adenomatous colorectal polyps) or to
detect a cancer in an early, treatable stage (as in
screening for breast cancer), and early detection should
positively influence the natural cause of the disease.
Even though MM is an incurable disease in most cases
and preventing the benign precursor MGUS from
progressing is impossible, screening might nevertheless
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be beneficial because detection of MGUS or
early-state MM is advantageous for morbidity and
delays mortality from the disease [27]. The criteria
further state that screening should be cost-effective and
continuous. The screening test for MM is cheap, and
early detection could prevent costly complications.
Screenings can be repeated at a certain interval.
The disadvantages of screening for MM are the
possible distress for relatives in whom MGUS or MM is
detected, since MGUS and MM are not curable and
progression from MGUS to MM can neither be predicted
nor prevented. However, weighing the advantages and
disadvantages for screening of healthy relatives in MM
families, we conclude that screening might be beneficial
for this distinct group. We suggest that screening should
comprise annual protein electrophoresis of blood and
urine and that it should be restricted to individuals with
more than one first-degree affected relative or to those
with one first-degree and at least one second-degree
relative with MM. Since MM is rarely diagnosed before
age 40, we propose that relatives should be screened
from this age. If families present with MM at a younger
age, then screening could be started five years earlier
than the youngest age at diagnosis (with the five years
being an arbitrary period). Counselling the families on
the limitations and possible advantages of screening
should of course precede any screening. We suggest
that this screening should be performed in a research
setting where the outcome can be closely monitored to
determine its clinical value and the psychological burden.
If, in the future, germline gene mutations are identified
as the cause of MM, more accurate risk estimates will
become available. If lifetime risks for mutation carriers
should indicate the need for screening, then
presymptomatic DNA testing can help in targeting this
surveillance.
In summary, families with multiple cases of MM
are rare. Although risk estimates for asymptomatic
relatives in these families are not yet available,
a clinically significant risk of developing MM cannot
be excluded. In a research setting, these families could
be offered screening for MM.
R Re ef fe er re en nc ce es s
1. Munshi NC, Tricot G, Barlogi B. Plasma Cell Neoplasms. In:
DeVita Jr. VT, Hellman S, Rosenberg SA. Cancer: Principles and
Practice of Oncology; 6th ed. Philadelphia, PA: Lippincott
Williams & Wilkins 2001: 2465-2499.
2. Selby P , Gore M. Myeloma and Other Plasma Cell Malignancies.
In Peckham M, Pinedo H. Veronesi U. Oxford Textbook of Onco-
logy. Vol. 2. Oxford, Oxford University Press 1995: 1852-1878.
3.  Association of Comprehensive Cancer Centres, The
Netherlands. 2003.
4. Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ,
Bergsagel PL, Kyle RA, Greipp PR, Witzig TE, Reeder CB, Lust
JA, Russell SJ, Hayman SR, Roy V, Kumar S, Zeldenrust SR,
Dalton RJ, Stewart AK. Treatment of newly diagnosed multiple
myeloma based on Mayo Stratification of Myeloma and
Risk-adapted Therapy (mSMART): consensus statement. Mayo
Clin Proc 2007; 82: 323-341.
5. Grosbois B, Jego P , Attal M, Payen C, Rapp MJ, Fuzibet JG,
Maigre M, Bataille R. Familial multiple myeloma: report of fifteen
families. Br J Haematol 1999; 105: 768-770.
6.  Lynch HT, Sanger WG, Pirruccello S, Quinn-Laquer B,
Weisenburger DD. Familial multiple myeloma: a family study and
review of the literature. J Natl Cancer Inst 2001; 93: 1479-1483.
7. Sobol H, Vey N, Sauvan R, Philip N, Noguchi T, Eisinger F. Re:
familial multiple myeloma: a family study and review of the
literature. J Natl Cancer Inst 2002; 94: 461-462.
8.  Segel GB, Lichtman MA. Familial (inherited) leukemia,
lymphoma, and myeloma: an overview. Blood Cells Mol
Dis 2004; 32: 246-261.
9. Lynch HT, Watson P , Tarantolo S, Wiernik PH, Quinn-Laquer B,
Isgur Bergsagel K, Huiart L, Olopade OI, Sobol H, Sanger W,
Hogg D, Weisenburger D. Phenotypic heterogeneity in multiple
myeloma families. J Clin Oncol 2005; 23: 685-893.
10. Altieri A, Chen B, Bermejo JL, Castro F, Hemminki K. Familial
risks and temporal incidence trends of multiple myeloma. Eur J
Cancer 2006; 42: 1661-1670.
11. Landgren O, Linet MS, McMaster ML, Gridley G, Hemminki K,
Goldin LR. Familial characteristics of autoimmune and
hematologic disorders in 8,406 multiple myeloma patients:
a population-based case-control study. Int J Cancer 2006;
118: 3095-3098.
12. Baris D, Silverman DT, Brown LM, Swanson GM, Hayes RB,
Schwartz AG, Liff JM, Schoenberg JB, Pottern LM, Greenberg RS,
Stewart PA. Occupation, pesticide exposure and risk of multiple
myeloma. Scand J Work Environ Health 2004; 30: 215-222.
13. Lewis EB. Leukemia, multiple myeloma, and aplastic anemia in
American radiologists. Science 1963; 142: 1492-1494.
14. Alexander DD, Mink PJ, Adami HO, Cole P , Mandel JS, Oken MM,
Trichopoulos D. Multiple myeloma: A review of the epidemiologic
literature. Int J Cancer 2007; 120 Suppl 12: 40-61.
15. Horwitz LJ, Levy RN, Rosner F. Multiple myeloma in three siblings.
Arch Intern Med 1985; 145: 1449-1450.
16. Engelhardt M, Ihorst G, Behringer D, Finke J, Roth B. Incidence
of monoclonal B-cell disease in siblings of patients with multiple
myeloma. Haematologica 2006; 91: 274-276.
17.  Ogmundsdottir HM, Haraldsdottirm V, Johannesson GM,
Olafsdottir G, Bjarnadottir K, Sigvaldason H, Tulinius H.
S Sc cr re ee en ni in ng g   f fo or r   h he ea al lt th hy y   r re el la at ti iv ve es s   i in n   f fa am mi il li ia al l   m mu ul lt ti ip pl le e   m my ye el lo om ma a
Inclusion criteria
Individuals with
– more than one first-degree relative diagnosed with multiple
myeloma, or
– one first-degree and at least one second-degree relative with
multiple myeloma
Screening programme
Annual protein electrophoresis to test immunoglobulins in blood 
and urine, starting at age 40 years. If families present with MM
at a younger age, then screening could be started at say five
years earlier than the youngest age at diagnosis in those families.
This screening should be performed in a research setting
Familial Multiple Myeloma: Report on Two Families and Discussion of Screening OptionsH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2007; 5(2) 78
Familiality of benign and malignant paraproteinemias.
A population-based cancer-registry study of multiple myeloma
families. Haematologica 2005; 90: 66-71.
18. Brown EE, Lan Q, Zheng T, Zhang Y, Wang SS, Hoar-Zahm S,
Chanock SJ, Rothman N, Baris D. Common variants in genes
that mediate immunity and risk of multiple myeloma. Int J
Cancer 2007; 120: 2715-2722.
19. Higgins MJ, Fonseca R. Genetics of multiple myeloma. Best Pract
Res Clin Haematol 2005; 18: 525-536.
20. Liebisch P , Dohner H. Cytogenetics and molecular cytogenetics
in multiple myeloma. Eur J Cancer 2006; 42: 1520-1529.
21. Hemminki K. Re: familial multiple myeloma: a family study and
review of the literature. J Natl Cancer Inst 2002; 94: 462-463.
22. Eriksson M, Hallberg B. Familial occurrence of hematologic
malignancies and other diseases in multiple myeloma:
a case-control study. Cancer Causes Control 1992; 3: 63-67.
23. Brown LM, Linet MS, Greenberg RS, Silverman DT, Hayes RB,
Swanson GM, Schwartz AG, Schoenberg JB, Pottern LM,
Fraumeni JF Jr. Multiple myeloma and family history of cancer
among blacks and whites in the U.S. Cancer 1999; 85: 2385-
2390.
24. Hemminki K, Eng C. Clinical genetic counselling for familial
cancers requires reliable data on familial cancer risks and
general action plans. J Med Genet 2004; 41: 801-807.
25. Daugherty SE, Pfeiffer RM, Mellemkjaer L, Hemminki K, Goldin
LR. No evidence for anticipation in lymphoproliferative tumors
in population-based samples. Cancer Epidemiol Biomarkers
Prev 2005; 14: 1245-1250.
26. Hodgson SV, Foulkes WD, Charis E, Maher ER. A practical guide
to human cancer genetics. Chapter 9. Blood and lymph. 3
rd ed.
Cambridge, Cambridge University Press; 2007, 120-131.
27. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR,
Plevak MF, Melton LJ. A long-term study of prognosis in
monoclonal gammopathy of undetermined significance. N Engl
J Med 2002; 346: 564-569.
28. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF,
Offord JR, Dispenzieri A, Katzmann JA, Melton LJ. Prevalence
of monoclonal gammopathy of undetermined significance. 
N Engl J Med 2006; 54: 1362-1369.
29. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined
significance. UpToDate 2006: http://www.utdol.com/utd/index.do.
30. Wilson JM, Jungner YG. Principles and practice of mass
screening for disease. Bol Oficina Sanit Panam 1968; 65: 281-
393.
31. Hussein MA. Multiple myeloma: most common end-organ
damage and management. J Natl Compr Canc Netw 2007;
5: 170-178.
Erica H. Gerkes, Mirjam M. de Jong, Rolf H. Sijmons, Edo Vellenga